Poseida Therapeutics Inc. (PSTX)
$9.50
$0.00 (0.00%)As on 08-Jan-2025 09:30EDT
Market cap
$926 Mln
Revenue (TTM)
$151 Mln
P/E Ratio
--
P/B Ratio
10.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.2
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
97,466,704
8 Years Aggregate
CFO
$-469.90 Mln
EBITDA
$-323.51 Mln
Net Profit
$-337.28 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Poseida Therapeutics (PSTX)
| -1.0 | 1.5 | 257.1 | 199.7 | 14.1 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Poseida Therapeutics (PSTX)
| 183.3 | -36.6 | -22.2 | -37.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Poseida Therapeutics (PSTX)
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase... I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. As of January 7, 2025, Poseida Therapeutics, Inc. operates as a subsidiary of Roche Holdings, Inc. Read more
-
Executive Chairman of the Board
Mr. Mark J. Gergen J.D.
-
Executive Chairman of the Board
Mr. Mark J. Gergen J.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Poseida Therapeutics (PSTX)
What is the current share price of Poseida Therapeutics Inc (PSTX) Today?
The share price of Poseida Therapeutics Inc (PSTX) is $9.50 (NASDAQ) as of 08-Jan-2025 09:30 EDT. Poseida Therapeutics Inc (PSTX) has given a return of 14.13% in the last 3 years.
What is the current PB & PE ratio of Poseida Therapeutics Inc (PSTX)?
Since, TTM earnings of Poseida Therapeutics Inc (PSTX) is negative, P/E ratio is not available.
The P/B ratio of Poseida Therapeutics Inc (PSTX) is 10.62 times as on 08-Jan-2025, a 99 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-2.46 |
2.92 |
2022 |
-7.12 |
2.43 |
2021 |
97.39 |
2.75 |
2020 |
276.55 |
2.59 |
2019 |
-- |
-- |
What is the 52 Week High and Low of Poseida Therapeutics Inc (PSTX)?
The 52-week high and low of Poseida Therapeutics Inc (PSTX) are Rs -- and Rs -- as of 29-Aug-2026.
What is the market cap of Poseida Therapeutics Inc (PSTX)?
Poseida Therapeutics Inc (PSTX) has a market capitalisation of $ 926 Mln as on 08-Jan-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Poseida Therapeutics Inc (PSTX)?
Before investing in Poseida Therapeutics Inc (PSTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.